Rickets Market Share

Rickets Market Scenario:

The Rickets Market is anticipated to reach USD 1,503.50 Million by 2030 at 5.90% CAGR during the forecast period 2022-2030Rickets is a condition characterised by the deficiency of Vitamin D that affects bone development in children which can lead to bone deformities. Rickets in adults is known as osteomalacia. The disease causes softening of the bones, bone pain, poor growth and deformities of the skeleton, such as bowed legs, curvature of the spine, and thickening of the ankles, wrists and knees. According to the Vitamin D Council, in 2016, approximately 1 billion individuals worldwide, which is nearly 15% of the world’s population, are vitamin D deficient or insufficient i.e. suffering from rickets. Increasing prevalence of rickets, poor diet and changing lifestyle have driven the growth of the rickets market. In the recent decades, the number of patients suffering from rickets is increasing continuously. Smoking is considered as one of the risk factors of rickets. According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing healthcare expenditure, increasing geriatric population, and increasing demand for vitamin D supplements have fuelled the growth of the market. Strong encouragement from the government have also contributed to the growth of the rickets market. However, lack of presided treatment and high cost of the drugs and supplements may lead to hinder the growth of the rickets market.

Intended Audience

• Pharmaceutical companies


• Biotechnological institutes


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Market Research and Consulting Service Providers

Figure 1:- Global Rickets market share, by causes

Sources: WHO, annual reports, press release, white paper, and company presentation

Segmentation

The rickets market is segmented on the basis of types, causes, therapy, and end users.

On the basis of types, the rickets market is segmented into vitamin D-related rickets, hypocalcemia-related rickets, hypophosphatemia-related rickets, and others. Vitamin D-related rickets is further segmented into vitamin D deficiency, and vitamin D-dependent rickets. Hypophosphatemia-related rickets is further segmented into congenital, hypophosphatemia, Fanconi's syndrome, and others.

On the basis of causes, the rickets market is categorised into sunlight, diet, genetics and others

On the basis of therapy, the rickets market is segmented into diagnosis and treatment. Diagnosis is further segmented into blood tests, bone density scan, radiography, and others. Treatment is subsegmented into diet & sunlight therapy, supplementation, and others.

On the basis of end users, the rickets market is segmented into hospital, clinics, and others. 

Regional Analysis

America dominates the rickets market owing to a well-developed healthcare sector and huge demand for vitamin supplements. Apart from this, increasing number of patients, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to a research, approximately 35% of the U.S. population has vitamin D deficiency. Additionally, increasing geriatric population, increasing smoking population and increasing awareness among the people regarding different types of diseases and well-developed technology has also contributed to the growth of the rickets market.

Europe is the second largest rickets market, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development will drive the rickets market. In recent years, there's been an increase in cases of rickets in the UK. The number of rickets cases is still relatively small. Around 700 cases were diagnosed in hospitals in England in 2014, however a significant number of people in the UK have low levels of vitamin D in their blood.

Asia Pacific is the fastest growing region for the rickets market due to the presence of a huge patient population, continuously developing economies, and presence of huge opportunity in the rickets market.

On the other hand, the Middle East & Africa has the least share in the rickets market due to presence of poor economy especially in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation 

Key players for rickets market

The key players for the rickets market are Koninklijke DSM N.V. (the Netherlands), Nestlé S.A. (Switzerland), ADM Alliance Nutrition, Inc. (U.S.), Groupe Danone S.A. (France), Abbott (U.S.), Kraft Foods Group, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer (U.S.), and Sun Pharmaceutical Industries Ltd (India)